UBS initiated coverage on Perspective Therapeutics with a new price target
$CATX
Medical/Dental Instruments
Health Care
UBS initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $20.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $20.00 | Buy | UBS |
| 10/1/2024 | $25.00 | Outperform | Wedbush |
| 9/25/2024 | $21.00 | Buy | Truist |
| 7/25/2024 | $24.00 | Buy | BofA Securities |
| 5/9/2024 | Overweight | Cantor Fitzgerald |
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
UBS initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $20.00
Wedbush initiated coverage of Perspective Therapeutics with a rating of Outperform and set a new price target of $25.00
Truist initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $21.00
B of A Securities analyst Alec Stranahan initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Buy rating and announces Price Target of $24.
Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.
Cantor Fitzgerald analyst Louis Chen reiterates Perspective Therapeutics (AMEX:CATX) with a Overweight.
SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago. The presentation entitled "Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)" will be p
SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 have been selected for a poster presentation at the 21st International Congress of the Society for Melanoma Research ("SMR"), being held on October 10-13, 2024 in New Orleans, Louisiana. The title of the poster presentation for the Phase 1/2a study of [212Pb]VMT01 is "First in Human Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Melanoma (MM)." "We are looking forward
First Quarter 2024 Worldwide revenue of $370.0 million, an increase of 23.0% from first quarter 2023 GAAP fully diluted net income per share of $1.87, compared to GAAP fully diluted net loss per share of $0.04 in first quarter 2023. Adjusted fully diluted net income per share of $1.69 compared to adjusted fully diluted net income per share of $1.47 in the first quarter 2023The Company increases full year 2024 net revenue and earnings guidance and provides guidance for the second quarter 2024 BEDFORD, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fig
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
10-Q - Perspective Therapeutics, Inc. (0000728387) (Filer)
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to an updated list of additions to the membership list, considered to be final, as of Monday, June 10th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total mark
Phase I/2a clinical trials initiated: VMT-α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial cohorts expected by end of 2023.First patient dosed in Phase 1/2a dose escalation trial of VMT01 for treatment of MC1R-positive metastatic melanoma. RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period end
SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)
SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)
SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)
[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested (2.5 and 5.0 mCi)Eight of nine patients had durable control of disease. Six of nine patients had a measurable reduction of tumor volume, one of whom had a confirmed response as defined by RECIST v1.1. Signal of anti-tumor activity was generally more pronounced in patients with lower body weightPerspective is continuing all required activities to pursue dose escalation according to Safety Monitoring Committee recommendations; recruitment is ongoing at 5.0 mCi SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company
SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago. The presentation entitled "Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)" will be p
Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated metastatic melanoma, based on preliminary results presented at the 21st International Congress of the Society of Melanoma Research in OctoberPresenting initial results from the company-sponsored Phase 1/2a study of [212Pb]VMT-α-NET in patients with RPT-naïve neuroendocrine tumors at the upcoming 2024 North American Neuroendocrine Tumor Society Symposium in NovemberShipping of investigational product started in October from a second manufacturing facility in Somerset, New Jersey; additional facility expansion activities ongoingOn track to adva
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)